Free Trial
Joseph Stringer

Joseph Stringer Analyst Performance

Senior Analyst at Needham & Company LLC

Joseph Stringer is a stock analyst at Needham & Company LLC focused in the medical sector, covering 19 publicly traded companies. Over the past year, Joseph Stringer has issued 44 stock ratings, including buy and hold recommendations. While full access to Joseph Stringer's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Joseph Stringer's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
111 Last 4 Years
Buy Recommendations
87.39% 97 Buy Ratings
Companies Covered
19 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy87.4%97 ratings
Hold12.6%13 ratings
Sell0.0%0 ratings

Out of 111 total stock ratings issued by Joseph Stringer at Needham & Company LLC, the majority (87.4%) have been Buy recommendations, followed by 12.6% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
19 companies

Joseph Stringer, an analyst at Needham & Company LLC, currently covers 19 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
18 companies
94.7%
Manufacturing
1 company
5.3%

Joseph Stringer of Needham & Company LLC specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
16 companies
84.2%
MED - DRUGS
2 companies
10.5%
Miscellaneous
1 company
5.3%

About Joseph Stringer

Joseph Stringer joined Needham & Company in 2017, where he covers biotechnology companies. Prior to Needham, Joseph worked as a research scientist at Ra Pharmaceuticals. He conducted postdoctoral work at Yale University, earned his Ph.D. in Chemistry from the University of Wisconsin – Madison, and received a B.S. in Chemistry from Southern Illinois University – Carbondale.
Follow on LinkedIn

Joseph Stringer's Ratings History at Needham & Company LLC

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
3/31/2026Downgrade$40.27Hold
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
3/27/2026Initiated Coverage$16.25$50.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
3/25/2026Boost Price Target$73.16$105.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3/17/2026Boost Price Target$33.96$40.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3/17/2026Lower Price Target$90.51$130.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2/26/2026Lower Price Target$98.07$139.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2/25/2026Boost Price Target$81.09$103.00Buy
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2/24/2026Boost Price Target$7.43$18.00Buy
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/23/2026Reiterated Rating$149.74$170.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2/12/2026Lower Price Target$309.64$510.00Buy
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/11/2026Boost Price Target$147.23$170.00Buy
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2/9/2026Reiterated Rating$7.19$14.00Buy
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
1/13/2026Lower Price Target$23.20$28.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
1/12/2026Boost Price Target$398.29$529.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
1/9/2026Boost Price Target$101.53$148.00Buy
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
1/7/2026Boost Price Target$44.85$110.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
12/11/2025Boost Price Target$119.00$145.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
11/14/2025Downgrade$217.79Hold
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
11/13/2025Boost Price Target$126.57$140.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
11/7/2025Boost Price Target$98.64$135.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
11/4/2025Boost Price Target$107.17$122.00Buy
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
10/31/2025Reiterated Rating$118.44$133.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
10/30/2025Boost Price Target$71.88$90.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
10/27/2025Downgrade$49.15$65.00Hold
Moderna, Inc. stock logo
MRNA
Moderna
10/20/2025Reiterated Rating$26.01Hold
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
10/10/2025Boost Price Target$29.90$35.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
10/8/2025Boost Price Target$71.12$78.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9/24/2025Boost Price Target$87.51$100.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
9/10/2025Boost Price Target$46.98$65.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
9/2/2025Boost Price Target$56.47$70.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
8/25/2025Reiterated Rating$42.69$55.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
8/8/2025Reiterated Rating$61.73$74.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
7/31/2025Boost Price Target$393.00$478.00Buy
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
7/25/2025Upgrade$113.20$133.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
7/9/2025Reiterated Rating$85.44$95.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
7/1/2025Reiterated Rating$11.35$22.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
6/26/2025Boost Price Target$321.94$377.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
6/23/2025Boost Price Target$40.74$54.00Buy
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
6/6/2025Reiterated Rating$9.58$28.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
6/4/2025Boost Price Target$23.30$36.00Buy
Your $29.97 book is free today (Ad)

Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel

Normally $29.97. Today it's free. Grab your copy now.
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
5/23/2025Reiterated Rating$25.70$35.00Buy
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
5/22/2025Reiterated Rating$4.51$14.00Buy
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
5/21/2025Reiterated Rating$109.11Hold
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5/14/2025Lower Price Target$1.28$12.00Buy
Annexon, Inc. stock logo
ANNX
Annexon
5/13/2025Lower Price Target$1.77$11.00Buy
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
5/12/2025Lower Price Target$5.40$14.00Buy
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
5/7/2025Lower Price Target$17.78$29.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5/7/2025Boost Price Target$64.90$72.00Buy
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
5/6/2025Reiterated Rating$500.19Hold
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
4/30/2025Lower Price Target$30.84$55.00Buy
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4/25/2025Reiterated Rating$106.15Hold
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
4/21/2025Reiterated Rating$4.03$28.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
4/15/2025Reiterated Rating$28.68$60.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
4/10/2025Reiterated Rating$17.47$35.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
4/9/2025Reiterated Rating$224.32$320.00Buy
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
4/9/2025Reiterated Rating$4.25$28.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
4/9/2025Reiterated Rating$5.90$22.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
4/9/2025Reiterated Rating$24.08$60.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
4/8/2025Reiterated Rating$54.96$66.00Buy
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
4/8/2025Reiterated Rating$32.51$90.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
4/8/2025Reiterated Rating$27.57$60.00Buy
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
4/8/2025Reiterated Rating$0.90$15.00Buy
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
4/2/2025Reiterated Rating$5.12$28.00Buy
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
4/1/2025Lower Price Target$37.76$90.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
3/21/2025Reiterated Rating$253.60$320.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3/18/2025Boost Price Target$52.34$66.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3/18/2025Reiterated Rating$8.67$22.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3/17/2025Reiterated Rating$32.78$60.00Buy
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
3/11/2025Lower Price Target$1.06$15.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3/7/2025Reiterated Rating$23.61$35.00Buy
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3/6/2025Reiterated Rating$5.67$28.00Buy
Annexon, Inc. stock logo
ANNX
Annexon
3/4/2025Reiterated Rating$2.39$16.00Buy
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
3/4/2025Reiterated Rating$1.38$10.00Hold
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
3/3/2025Reiterated Rating$0.35Hold
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2/27/2025Reiterated Rating$9.20$19.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2/27/2025Reiterated Rating$53.32$64.00Buy
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2/26/2025Reiterated Rating$79.35$140.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2/26/2025Reiterated Rating$245.20$320.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2/20/2025Reiterated Rating$31.81$60.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2/19/2025Reiterated Rating$57.55$64.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
2/18/2025Reiterated Rating$9.74$22.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2/14/2025Reiterated Rating$264.89$320.00Buy
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/12/2025Reiterated Rating$96.14Hold
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2/11/2025Reiterated Rating$85.94$14.00Buy
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2/11/2025Reiterated Rating$469.97Hold
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2/10/2025Lower Price Target$7.79$10.00Buy
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
1/31/2025Reiterated Rating$438.40Hold
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
1/29/2025Reiterated Rating$0.93Hold
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
1/13/2025Reiterated Rating$237.98$320.00Buy
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
1/10/2025Reiterated Rating$6.95$28.00Buy
CODE RED: AI Meltdown Imminent? (Ad)

After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel

See the five simple steps to prepare before it's too late